Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 10/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 4/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 4/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843467 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| Hydrochloric Acid SCHEMBL29454390 | 0.99 | CHRNB2 (0.98) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL4727391 | 0.92 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL2495855 | 0.92 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL4726141 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL2501437 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL7674769 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL16321698 | 0.87 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL14940937 | 0.87 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL7666187 | 0.87 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20210077478-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2021-03-18 | — | — | US | claimed |
| EP-3713574-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | The Governors of the University of Alberta (CA) | 2020-09-30 | — | — | EP | claimed |
| CN-111629726-A | Method for combatting respiratory depression by activating neuronal heterotopic nicotinic acetylcholine receptors | 阿尔伯塔大学理事会 | 2020-09-04 | — | — | CN | claimed |
| WO-2019100155-A1 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2019-05-31 | — | — | WO | claimed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010045212-A2 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INCSTATUTS (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008011484-A2 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011484-A2 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2005004818-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNB2 36/4885CHRNA4 4/4885CHRNA2 10/4885 |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | CHRNB2 11/4885CHRNA4 3/4885CHRNA2 2/4885 |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | CHRNB2 1/4885CHRNA4 15/4885CHRNA2 2/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | CHRNB2 5/4885CHRNA4 4/4885CHRNA2 2/4885 |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | CHRNA5, CHRNA2, CHRNA10 | CHRNB2 7/4885CHRNA4 4/4885CHRNA2 2/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CHRNB2 41/4885CHRNA4 76/4885CHRNA2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.